37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20,2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1.	Submission required under 37 C.F.R. § 1.114	
a.	☐ Previously submitted	
	i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on (Any unentered amendment(s) referred to above will be entered)	
	ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	
	iii.	
b.	<u>Enclosed</u>	
	i. ☐ Amendment/Reply _ pages	
	ii. ☐ Affadavit(s)/Declaration(s) pages	
	iii. Information Disclosure Statement (IDS) 1 page	
	iv. 🗷 Form PTO 1449 <u>1</u> pg. & <u>7</u> References	
	v. Return Receipt Postcard (MPEP 503) (specifically itemized)	
	vi. Other	
2.	<u>Miscellaneous</u>	
. a.	Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c)	
	for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(I) required)
	Other	
3.	The RCE fee under 37 C.F.R. § 1.117(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.	
a	The Director is hereby authorized to charge the following fees or credit any overpayments, to	
	Deposit Account No. <u>19-2570.</u>	
	🗷 General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensio	ns
	of time, relating to this application. (37 CFR 1.136(a)(3))	
	i. RCE fee required under 37 C.F.R. § 1.17(e). \$790.00	
	i. \square () Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)	
	i. Additional Fees	
	v. E Total Fee to be charged to Deposit Account 19-2570 \$790.00	

n:\wjd\paroxetine\P312220 Paxil CR\RCE-4.doc

CORRESPONDENCE ADDRESS

P.O. Box 1539

Address

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

King of Prussia, PA 19406-0939 Telephone (610) 270-5023 Facsimile (610) 270-5090 02/06/2006 EFLORES 00000056 192570 10024858 790.00 DA

RESPECTFULLY SUBMITTED.

Wayne J! Dustman

33,870

Signature

Registration No.

NAME